Company news

Rigel Pharmaceuticals, Inc. news in 2025

Rigel Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

December 7, 2025

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

November 26, 2025

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

November 17, 2025

Rigel to Present at the Jefferies Global Healthcare Conference in London

November 12, 2025

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

November 4, 2025

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

November 3, 2025

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

October 29, 2025

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS

October 8, 2025

Rigel to Participate in Upcoming September Investor Conferences

August 26, 2025

Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update

August 5, 2025

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

July 29, 2025

Rigel to Present at the Jefferies Global Healthcare Conference

May 28, 2025

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

May 22, 2025

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

April 29, 2025

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

March 27, 2025

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

March 10, 2025

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 4, 2025

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

February 25, 2025

Rigel Provides Business Update and 2025 Outlook

January 12, 2025

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

January 8, 2025

Calls in 2025

Decks in 2025